samedan logo
 
 
 
spacer
home > pmps > summer 2003 > controlled release of pharmaceutical proteins from hydrogels
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Controlled Release of Pharmaceutical Proteins from Hydrogels

The therapeutic potential of many pharmaceutical proteins would highly benefit from the availability of controlled release systems for the constant or pulsed release of the intact protein. Several potential candidates for controlled release strategies are listed in Table 1. At present, alternative routes of administration to the parenteral route show little promise except for the pulmonary route.

This article focuses on parenteral delivery systems. So, we 'stick to the needle' but use controlled release delivery systems for these proteins: to produce the desired pharmaco-kinetic profile, for example to prevent high initial plasma concentrations (often 'the flatter, the better'); to reduce the injection frequency and improve patient-friendliness of the therapy; and to reduce the necessity of frequent involvement of trained medical personnel.

A number of strategies have been developed to control the release of proteins as a function of time (1). Proteins have been formulated in amorphous form or as crystals (for example insulin) to ensure release over a short period of up to two days. A second strategy uses a pump with a catheter and fixed needle to administer drugs for local or systemic delivery. These pumps have the advantage of control over pump rate and proven reliability of the technology, but even the miniaturised devices are expensive and become rather bothersome for the patients in the long run. Thirdly, liposomal dispersions release their content over periods of up to three weeks after subcutaneous injection.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ruud Verrijk, Gert Bos and Daan JA Crommelin of OctoPlus Technologies BV, and Wim E Hennink of the Utrecht Institute for Pharmaceutical Sciences, UIPS, Utrecht University

Ruud Verrijk PhD has over 15 years' experience in the pharmaceutical analysis of drugs. He worked as a Postdoc at the Netherlands Cancer Institute, where he was responsible for the formulation and analysis of cytostatics in microspheres, targeting and bioanalysis of cytotoxic precursor drugs. He is author of more than 15 papers on pharmaceutical analysis, drug formulation and pharmacology. He is currently working at OctoPlus Technologies as Manager Research Projects on protein delivery with hydrogels and on non-viral polymeric DNA delivery systems.

Gert Bos PhD obtained his master's in Chemical Technology in 1993 at the University of Twente. He earned his PhD in Biomaterial Science from the same university after which he moved to a business development position at OctoPlus in the Netherlands.

Professor Daan Crommelin PhD is a Professor at the Department of Pharmaceutics at Utrecht University. He is Scientific Director of the Utrecht Institute for Pharmaceutical Sciences (UIPS) and Adjunct Professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. His research focuses on advanced drug delivery and drug targeting strategies. Professor Crommelin is also Chief Scientific Officer of OctoPlus.

Professor Wim Hennink PhD studied biochemistry at the Agricultural University of Wageningen. He obtained his PhD at the Twente University of Technology on a thesis entitled: Albumin-heparin Conjugate as a Coating for Biomaterials. He previously worked as a Development Engineer within the R&D Department of Fasson in Leiden. In July 1992 he took up his present position and became Head of the Department of Pharmaceutics in 1996. Professor Hennink is European Editor of the J. Controlled Release.
spacer
Ruud Verrijk
spacer
spacer
spacer
Gert Bos
spacer
spacer
spacer
Professor Daan Crommelin
spacer
spacer
spacer
Professor Wim Hennink
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Introduces Parteck® COAT Excipient, a Fast-Dissolving Material for Immediate Release Coating

• Designed to simplify the formulation and coating process for tablets • Optimized particle size leads to fast dissolving and increases coating process efficiency Merck has launched its Parteck® COAT excipient, a new functional material designed for immediate release film coating applications. Parteck® COAT is a particle engineered polyvinyl alcohol (PVA) with a unique particle structure that enables rapid dissolution even at low temperatures leading to an increased process efficiency.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement